Unassociated Document

0000950103-07-001559.txt : 20070621 0000950103-07-001559.hdr.sgml : 20070621 20070621115747 ACCESSION NUMBER: 0000950103-07-001559 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20070619 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070621 DATE AS OF CHANGE: 20070621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 07933018 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp06032e_8k.htm Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2007

Shire plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)

	0-29630		98-0484822
	(Commission File Number)		(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code 44 1256 894 000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

Other Events

Shire plc has issued the press releases attached hereto as Exhibit 99.01, Exhibit 99.02, Exhibit 99.03, Exhibit 99.04, Exhibit 99.05 and Exhibit 99.06 which are incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.01		Press Release dated June 19, 2007
99.02		Press Release dated June 20, 2007
99.03		Press Release dated June 20, 2007
99.04		Press Release dated June 20, 2007
99.05		Press Release dated June 20, 2007
99.06		Press Release dated June 21, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC

By:	/s/ A C Russell

	Name:	Angus Russell
	Title:	Chief Financial Officer

Dated: June 21, 2007

EXHIBIT INDEX

Number	Description
99.01 99.02 99.03	Press Release dated June 19, 2007 Press Release dated June 20, 2007 Press Release dated June 20, 2007
99.04 99.05 99.06	Press Release dated June 20, 2007 Press Release dated June 20, 2007 Press Release dated June 21, 2007

EX-99.1 2 dp06032e_ex9901.htm Unassociated Document

		EXHIBIT 99.01

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

19 June 2007

Notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify): Revised due to DTR rules – see Section 13	Yes

3. Full name of person(s) subject to the notification obligation:	The Goldman Sachs Group Inc
4. Full name of shareholder(s) (if different from 3.):	Goldman Sachs & Co
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	14 June 2007
6. Date on which issuer notified:	18 June 2007
7. Threshold(s) that is/are crossed or reached:	3%
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
US82481R1068		Below 3%			15,115,773 (5,038,591 ADRs)		2.71%
GB00B0KQX869		Below 3%			1,708,016		0.31%

Registered in England 5492592 Registered Office as above

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date	Exercise/Conversion Period/ Date	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Total (A+B)
Number of voting rights	% of voting rights
16,823,789	3.02%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

The interest in 1,708,016 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited.

The interest in 15,070,260 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers of 5,023,420 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).

The interest in 45,513 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as discretionary manager for its customers of 15,171 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	General Email Contact: shareholderdisclosures@gs.com
14. Contact name:	Joanne Wall/Sean Rogers
15. Contact telephone number:	44 (20)7051-1704/ 44(20)7552-9205

(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#D`K`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`AGN+>TB::YGAMH8P2TL\B0QH`,DL[D!1CWI MI.]HIW[)?H@V\K?(^;]?_;"_9L\-7=S8:C\6O"LEW:,\=Q!IMZ-4>&1"0\3C M3Q+B0$$;>N01U%>Y2X9SRK&,HY=5C&6W.N3Y^];3_-=SFGB\-3WJQ6K6CZK? M;MU,F3]MO]E^*UENC\6?#^V%=QMXSL#_SQL4A,TO?[B&M(\*Y]S**RZHO M-V4?G*_*OO%]/A5\1O#&I^+_#'BVP;1-"N8++7IM3$ MNBSZ%>71B%M;:Q::FD$VG2RM/$(Q,B;RXVYS7D8O)LRP->EA:^%E&M73=-0M M-5$M^24+J5NO*W;J:TZU*I%RA)"))RTDTDKJJJH))8`"I((/B#3`00<$$?:.N:]!91F?3+Z]O^O4^OR(52FTFIQL]M4=OINI:?JUC; M:EI5[;:AIUW&)K2]LIH[BUN(B2!)!-$Q21,@C*DC@UQ3ISHSE3J0=.<'9QDK M.+[-/8M-6TV+M0`4`%`!0`4`%`!0`4`%`!0!B>)?$.E^$?#NN^*-7$D;SW-_.+*V:5O+\L$O)^U9;D^4\-X:-6JX M>WM"-3$35W*;;M&C%IN-WI&,%[2?6^R^=JU\1C)NG235.^R6B7=NVBMO?S[V M,'PO^RAX[U[2O[1\'^%M;^+$QMIHC<^#A%8^`M-U6*4PRV3>-M5,%OXINK1U M(G@T-)K4D@)J>X,HZ:^>X'#5'3Q>(IX!IWY:S;KN&C4G0A>5)36WM6JBOK25 MKD4\&Y*7(G5>OO134+M_S67-:VO+>_,K.R;/)/B/\"_C!\+XEU'Q]\-_$7A/ M3)9TM8M0N--G_L3[1(KO':1:K&TUL\Y5)"$-PSD*3R!7;A,UR['/EP>,I5Y1 M7PPE'G275PTE;7=HYZN'KT=9TG!;7M:/EJM-OF^NMSTS]FC]J_X@?L]>);`0 M:C?:W\/;F[@7Q%X,O+AY[7["7*SW>@B9C_9.J1)))*@A,<4[J%G5LAX^#/,@ MPF<8>490C1QD8OV59*TD]TIVMS0>SO=Q3O&VQMA<95P\HJ]Z2T<6[*W==FKW M\]GTM^K?[7GASPA=_LY?'CXO^#%TY]'^*/@'X(3)?Z6BP6VOG3?B2FHVVMW5 MLL2;[R32]?TN(3R`2E(!'(,P@#X'AO$8JGG64Y7B>95,NKX_W9.[I\^$<7"+ MN_=4JMC5'ZK7JT](U(4K-:7M4O>WI):]3\5_P!GI%'Q[^">%48^ M+'P\Q\H&,>+=)]J_2LZ;_L?-M7_N>*_&A,\3#-_6,.KNWM(=?[R/ZQZ_GT^M M"@""Z4M;7"J"S-!*JJ!DDF-@``.I)JH_%'U7Y@?RM7/[+_[0[7-PR?`SXHE& MGF92/`GB(`@R,01_Q+NA'/O7[_\`V[E'_0WPG_A32Z_]OGR7U;%1]WV%16Z* M,K?@K']$?[)?A_6_"G[./PD\/>(](U'0-] MSZ;#)QH4DXN#4=4U9KY.UCZ)KPS<*`"@`H`*`"@`H`*`"@#S/XK_`!>\`?!3 MPG=>,?B%KMOHFEP^9%9P',VI:SJ"PR31:5HUA'^\O;^41G``6.,9DGDBA1Y$ M[\NRS&9IB(X7!474GHY/:%.+=G*:<15 MVZJ_,GXH?'_4/%6D2>`/AUX>T[X4_"2TEV:?X/\.;H]4UN"*+RH;K MX@>)O^/SQAJ+R--.1=LUO&TX"Q.T"2G[C`Y5##U(XK&UI8_,-.:M4^&GWCAZ M2:A0A:R]VTY6;CLUS:[W[?T;_`CXA? M"_QW\._"_P#PJ[7-#OM(T?P]HEB^BZ7QIZ?\`E8\!937WYH1\M=/+9_F_5GVK\9_A M_P"*?A7_`,$V]=^'OC.ZTV\\1^%-$\.:;>SZ/UHV5$O`>O:IX2^$_A MB#X@WVERFTN?%=_JNQ039B:=9;&%V1FMY9XBLK?G MF4\#5\31AB,RKRP49J\:,(*55)[.;;4:;>_+:A[6(S.G1;A2CSN+U? MV5HGI;?>VZL[O72_@'A/_@JU\1+34(_^$W^&/@[6-*)<2)X8O]8\.:C"&"A' MCDU.?689]AW$QF.+?D`.G6O8Q'`&`<7]5QM:A/2WM(PJQ\[J/LFK]+/3?4YH MYO.ZYJ*M?HVG9W_%:>MGM?3]8/@E\=O`WQY\!1>._`]Q/Y,1>UUK0[\10ZSX M=U:*%9Y=*U2*&22,2^4\38SZIB4O>UIU(W]G M5@W;GA=)VO=232<6FFCUZ%:%:G&I#1=5UB^J_P"&T/SJE_X*R:1%+)$?@=J) M,?"'X,?%>3X9WFJ1?%^TUJ[@T-/%<-E)H`T9K-6274&\/ MS#43*;L8*V]OMV'AL\>3A.$98G,LTRY8]4_[,=-.?L6_:>T3?P^U7+:W\TKG M76QJHT:55T]*G12M;KV_RMYE#]G_`/X*"^'?C;XWU+PI?^`6^'^FZ/X.\0^, M]2\3:IXQMM0L;+3O#IL&O3V]AJ*0M)$+C3O#5B+:[%I*P26. M6[OK:4H<26L;'Y?4R[@&\(SS/%RI2:3]C04;QO9VE5ES1O:Z:C!I/:3.>MFL M8MQH0O9_%+1.W9)I_/\`#4^]_@C\<8?&_P"SOX8^.'Q%GT#PA!>Z3K.I^(KF M.::TT'2X=(\0:MHWG+)?W$LD<4Q4W5IH-E!+>W-E)C,9N+ MK3I2N"\*$[1]5E_`%62A/,L8J":3=*A'FG&_1U)6@I='RQG&^TFEKY]7-80D MHT8`]6TSS29;;1+G7_#]^(2. M%BO;V^U:(2*>G6X`R[DM0QF(HSMO/V=2-[K7E4:;U5_M=O.^$, MWJ*_/1COIRMQT?36_P!_7MU/TK_9S_:\^%W[1L,]AX?DN_#?C2PADN;_`,$Z M]);#4C:1&(2ZEH]S;N8M9TM7GC1Y(Q%-$Q'GV\2O&TGP^=<-X_(^6=2U?"2: M4:]--14G>T*D7K3F[-I.\9?9DVFEZF'Q=&NDH/EG_*]&OT>S\[*]K'U37SYU M!0!\T_M,_M+>%?V66 M`2R*&DD:6.&%2\A:/WLM>6.S=M_2U]3P7X)_LS^-?B!XHL_CW^UA?#Q5XTD2"^\%?#N8H_A7P M'9SJTT4=SHQC-L=2BW0%+=-\<4B--.]U=E98/8S7/L-@L/+)^'8?5L-&\:^( M2:JUI)_9GI+E>MY.TFGRQ4(74L*&'J3E&OB[2FM80Z03UU5OB6B\K;MZGW9X MN\*:-XV\*>(?!FOVPN=#\3:+J.A:G;@(K&RU.UEM)C"65A%.B2[XY`I*2(CC ME17R.&Q%7!XBABJ$N6KAYQJ0?]Z+4E?;1VLUU3:.Z45*,H->[)-->OD?S0_M M$?LE_$_]GG5;^75].EUSP&MWY>C^.].C7^SKF"8YMH]4MDD:71]1"D)(DJ^2 M74^3+(IX_<5V2G'JFM;-72=SYC$X*IAI;CEC*4&G%N+6UCZL\!?MU_M,_#^UATZU M^(-QXDTV!@R6?C*RL_$DI`&!$=6U")M3$/HBWJ@?PXKP<7PMD>,DYSP,:,WU MHN5%>O)!JG?_`+<.RGF&*IV7/S+LTG^.^VG;K:^I^A7P(_X*;^'?$]]IGAKX MT:!;>#M1O9EM1XPT)KB3PP)G7$3ZEIMP\UWI432`*9HY[M%,JEECC5G7X[-> M!*M"%2ME5:5>--7]A4LJMNJA.*C&3[1<8MI:-NR?HX?,X2:A5C[-WLFMM6DK M]M]7MI>VME]-?MZNC_LC_%MXV5T>U\&NCH0R,C?$'PD5964X92"""."#7A<( M)KB/+TU9KZPFGHTUAJQT9@T\%5:=T^2S7^.)_-+:&[6ZMOL!G6]\^(6GV9F2 MX^TEU$`@92"LQD*[2"#DCFOVZR?NNUGH[[?/R/F8I\RBM'>R^?H?NK\,?^"8 M?PJLO"6E2?$[5/$NN>,;JTBN=772=272=(TVYG7S386$$,#33"W#")YYYG\U MXVD5(E<1K^58[CK'/$3C@*5*EAHNT.>+E.2_FE[R2N[M))63LVWJ?04LJHQA M%5;RGULVEKV2[?CKY6_.7]LW]F:R_9J\?:+IV@:K>:KX0\8Z9=ZKX>;4_+.I MV$FF7$%MJNF7D\"1QW?DR7=G+'.L<1,=XJ,I:)I)/L^&<[EG6#JU*M.-+$86 M<85%&ZB^=.4)Q3UCS)23C=ZQ;NDTEYN.P?U2:<'^[EMW3ZI]^Z?R]?;_`/@E M_P"-=2TGXN>-_`JS/_8OBSX?:AK$]J3^[&L>%[ZQ6PN5&/E<6&M:M&2,;A(N M<[5QYG'.%ISRS#8NUJN%Q,(1>WN5HRYH]OBIP?R\V;Y3.4:E2%_<:V_O=+?) M2OWT/S5O/^/NZ_Z^9_\`T:U?:GDGZ!?M* M*>GOX;_TB9[&._W+"]-?_;6?!>D7.KQR76EZ+)=+/XCMHM`N+6S+";4K:YU+ M3KV/3<)\TB3:CI]@3&.',2J002#]5-4TE.:2C1;FG*UH-1E'GUT3492UZ)NQ MY5.4XWA3_P"7GNV76[T^=]NJ/U"^'W_!+#QQKNA6&K>._B'IO@O4;VT@N7\. MV.@OKUWIKSJ)/LU_?_VO:0?:HU8+(D"2HKA@LSJ`Q^%Q?'N"P]6=+"X.>)A" M32J>T5*,K:7C%TY2L]TW9V^RCU*>4S=-.4_9S=G:VU^CVU7D['@?[4WC76?` M>A^%OV0-(UZ34O"OP4DOT\1:S;P2:4GC#Q1K6I7WB1>];J<1:?I%KKD=FD M+S2AKN.YG/W81%Z^186CB:E;B.=%4\3FBBZ<&U/ZO1A&-*RERQ]^JZ;G*22] MQQBK7G?'&572A#!QEI05I/1*3WVN[6V[WOT9WG[$O[%FF?'ZQU3X@_$*^U"R M\`Z9J,NB:9IFD7"6FHZ_K%K':W%Z\]VT3M::1;PW4<9\D+---(P62);=O.Y. M)^)I9,Z>$P<(RQE6/.Y33Y*=-MJ+237-.33M?W8I:I\RM6`P,:Z=6H[4T[** M=F[+7;5:M?CW3/N3XA?\$RO@=JGA;58?A[_PD'A/Q9'8N^BWMQKVH:SIDNH0 M1$P0:I9ZI+.?LD[C;(UN\#J7W@G;L;Y3!\^HTXTY*+>KB MX):QOHFFK*VE[GH5LLH.#5)>RFOA?2][NZ[/;RZ=C\.O#VO>,/A%X^L]9TN: M\\.>,_`OB%@R+(T4UGJFCWC6]_IMWY+@36[R0SVMQ"2TFR MOOVZ^2N9WQE^+/AGX)?#S7_B%XID!LM'@"V>G)-'!=ZUJUQE-/T>P+AO])N) M1U"/Y<:2RLI2)JO+,NKYIC*6#PZUF_>E:ZIPNN:G*I M+11V6S;Z)>;/SJ_9`^&GB3]HOQ[J7[77QM9=45=5N+/X8Z!*)!IFGOIDDEM) MJ%M8O^Z_LS3W8VUFIW%KNWNKJ3,T<RO"^)FOB:G9\K MEOSU+,K+5W4(O9+HTNEM?7?U_6:OSL]4X#Q[\4_ MA[\+K?3KKQ_XKTOPK;ZM//;:;+J;S(MY/;1I+<1P^3"YW)'(C'('#"NS!Y?C M<>AP6F?M#?L]^/-1LO!^G?$'P MEXCO]?G73K/0V$T_]HSSA@MLL-S9B-V<`@!B,].]=D\FSG!0EB98.KAX4%S2 MG=+D2ZW4KHA5J$FH*I%MZ)777R.!^(O[#?[.'Q&E:\O/`EKX;U)@V=0$RR> M'7=V))EN+73VCMKJ7<2=TT+GD^M=F"XKSK`I0CBG6IK[-9*>BTLG+WHKT:Z& M53`X:;NZ=GY-Q\ME9'P]\4?^"5TL$5UJ'PB\>23M%`TD/A[QA;Q>9<3*CL8H M=:TZ.)8%9@JJ);24\\MWKZG`M2BW9*__`#[E=OY37H<%7*4M M:,^5+I+\=5Y>6_4_(S7]`UGPIK>J^&_$.G7&D:YHE]<:;JFFW2A+BRO;60QS MP2A6925<'#*S*P(925()_0Z56G5I4ZU&:G2J14H26SC)737JCQI1E3DX27+* M+LUV9^H/A'XIZUX__P"":_QI\.Z_<&[O/AKJ_@_PWIUW([/(J35K1]K'#UXS&1E)!!X()!KZO-IRIY5F>=AE_M%!=/:05O)R2?WG]9M?SX?7GXZ?\%:(H_LGP-GV+YJW'Q`B#XPPC M:/P@Y3/]W./_0]$KW^-/\`D1/_`+"\-^54PRK^++^NDSX-O/\`C[NO^OF? M_P!&M7U9Y9^@7[2G_)G?[$_;_B3^./\`T=H]?)Y/IQ+Q3Y3PW_I$SV,=I@L+ MZ_\`MK/,OV$/"NE>+?VH_AG9:S;I=66ESZWXD2VE4-&]_P"']`U/5-)=E/!\ MG58+.X`/&;<5V<55ZF%R',)4I.$Y1A3NM+1JU80G]$2C\SDR^$98JFI?9O) M>JU1_317X8?4'\H'[1MW/>?M`?&ZXN6+2GXL?$"/)SQ';^*M4MX%&>BK!%&H M'0!1CBOZ"R:*AE&5)*UL'AG;:S=&#:MWNW?S/DL4W]9KWTM4DODFTOP.Q^&/ MQ,_:E\+^$K72?A3J?Q+L_!T=W?S6D7AC2M4N=)^V3W+MJ#136EG)&TQNMXDP MQ(8$'!&*QQN!R.O7<\?1PLL1RQ3=64%/E2]W1R3M;;35%TJN*A!1I>T4([%-=,][J%],]Q>7<[ M"P&Z:6>1Y&/=G)[UZM/%9=0ITZ-+$X>G2HQ4(156FE&,4E&*][9))(YY4Z[D MY.G.[=_AEU^1_0-^P-'XALOV8?!&C^)=)U/1=0T/4?%FFQ6>K6%SIMY]B/B; M4[^WD:WNT23RS]N=$1HWAK MPVGC*[7:WX@N=0T^V>8`X*6FG:6X0D9!U*?UK[#@#`0A@\1CVOWF(K>P M5MXPIJ,FEYSE-7_P1.#-JCYZ=.UJ:UTTN^OW*UO.Y^R_PV\+Z9X)^'W@OPEH MT,,&F^'_``QHNEVJP*JQN+73X(Y+@[``TD\HDF=^KO*S')8U^98[$3Q6,Q6( MJ-\]:K4F[].:3=O1+1+HE8]FE%4Z=.$=%&*2MZ?J=M7*6?GO_P`%)_AMJ'C; MX`1Z_H]C->ZC\.O$UGXEN([=#).GA^XL[S2M;E6->3'!]JL;R4_PQ6$K?PU] MGP/C887-IT*DE"&-I.G&^B]K&49P7_;R4XI=92BCSLSI.6'YHJSI._\`VZU9 M[>=G\C\"O!'B[5_`'C#PQXWT!HH]9\)ZYIFOZ9YZ>9;M>:7=Q7<,=Q'QOMY& MBV2)_$CL.]?K6)P]+%8>OA:R?L:\)4YI:/EFG%V?1V=T^CU/GJ4W2J0J1WA) M.WH[V^9_1_\`"+]MKX%?$_P[9ZC=>+=-\&:_Y2KJOASQ)<"QN+.Z55$S6]RX M\FZLFD+>7*'5F7[R`U^+9CPKFV7UI0IX>6)HW]RI27-==+Q6L96W5K7ZGU%' M&4*D8VFHR_E>CO:[.T\7?M8?L_>"]'O-7U'XF>'+Q;2!YH['1[M=3U"\D524 MMK2"U#!IY"-JAW09/)%(;C4K*QD96EMK&.&"QLEG9`% M-RUI:0O*5`!D=R.#7[7EF$>7Y?@\$Y\[PU)0`=7\+?\$VOCWXJU6W-K'\0/$GA+4]$5QM>?0=(\9^ M"]+M[PCLDVHKJIC_`+T:(XX<5\MC,73J\;91A:;UP5*O&IY5*F'KS:^4/9W\ M[KH=\:3I977;7*ZC@_ESQMZ>GSZGQ%^SU_R7OX*?]E8^'G_J6Z37TF=?\B?- MO^P/%?\`IB9P8;_>/O\` MT1X2K](\/OCS+TI?G,\7./\`F'_[?_\`;3Y;_P"";'_)RA_[)IXX_P#0]$KZ M#C3_`)$3_P"PO#?E5,,J_BR_KI,^#;S_`(^[K_KYG_\`1K5]6>6?H%^TI_R9 MW^Q/_P!@?QQC_O\`:/7R>3_\E+Q3T?/AK?\`@$SV,=_N6%]?_;6.[^\L)H-`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`"OQ;`T#F,R1::]U; MR8SEX9;OP#_X)G^,-5U73=>^-US;^'_#D2K=2>%M-N1< M:WJ#AT:.TOIX_P!WI\!`<2J,R=-IY-?)9OQOA:,)T M3V:Z'H8?*Y74JSY(JSY5ONG9]M+W]3](?VJ?ACJ?B7]EWQQ\,/AEXWMPRK)DK';0R.0.?EK] M&S3B+)*^69A0HX^$JM;#5Z<(V:O.=*48KYMH\:A@L13K49.G)*$X-Z;)23?X M']$]?C!](?F?_P`%%_@A\3OC+9_">+X;^%[GQ&_A^Y\8OJRVTL47V)=1B\-K M9%_-89\TV=SC'_/(U]UP7F>`RV6/>-Q,<,JBI*'-?WK.=[6[:7]4>7F5"K5] MBJ4')1Y[VZ7Y;?>>`?L-?LQ?&[X5_',^*?'7@B]T#0?^$$\5Z4+^>:!X_M^H M-I1M(,1N3ND$$N#C^`U['%6>95C,H>'P>,C6K?6*$^2*:?+%5.9_*Z^\QR_# M5J%5N4'%=WITE_F?(5Q^P]^T_)<3R+\+]3VO-*Z_Z3:?=9V8?\M/0U]'_K/D M'_0QA]S.'ZAB?^?;^X^R?CG^S-\:_%/[,W[*_@?0?!-[>^)_`.F^+(/%>EI- M`LNE2:A+IAM%E9G"MY@@E(VD_=KYS+,[RJAGO$.*J8R-/#XJ5#V,VG::C&:E M9+LVCT<5AZL\+AZ<8-2@]4NFC1@_L3?LM_'/X8?M"^%?&'C?P+>Z%X=T_2O% M,%UJ,TUN\<,NH>'M0L[1"L;DYDN)HT&!U:M.)\]RG&Y+BL-A,9&K7G*ERP2: M>E6$I?@FS'`X2M0Q$9R@XQ2EJU;=,_<&ORD]T\'_`&A/V?O!G[1'@A_"7BE' MM+VRE>]\.>(+1$.H:%J3($::#<,26TR*J30-\LBJN>47'KY-G&)R7%*O0]ZG M+2I2;M&%A*G6%;W;75W:6 MS72_4\&IE^)I27+&ZULXO:VNO;]3S"+]G/\`:,UB:WL1\,_'UZ[2)'!%<6ER M\<9/R!@;B;9$H!QGC`->@\XRB"6XM%SF2 M/$A*BOB.(.,J\M?>[/34]+"9:Z4U4KV;CK&*V MOO=^A^P]?FQ[`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! &0`4`?__9 ` end EX-99.2 4 dp06032e_ex9902.htm Unassociated Document

		EXHIBIT 99.02

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

Shire in-licenses JUVISTA^® (human TGFβ3) from Renovo

·	Novel biopharmaceutical drug candidate for the prevention and reduction of scarring in connection with both therapeutic and cosmetic surgery – a market served by specialist physicians

·	In-license includes exclusive worldwide rights except for EU member states

·	Financial payments geared to success and linked to significant milestones

·	Renovo estimates a potential new multi-billion market opportunity in the U.S.

Basingstoke, UK and Philadelphia, US – June 20, 2007– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today the signing of an agreement with Renovo Group plc (LSE: RNVO) for the exclusive development and commercialization rights to JUVISTA^®, Renovo’s novel treatment in late phase 2 development for the prevention and reduction of scarring. Phase 3 trials are anticipated to commence in mid 2008.

Under the terms of the agreement Shire has the exclusive right to commercialize JUVISTA worldwide, with the exception of EU member states.

Matthew Emmens, Chief Executive of Shire said:

“This is a novel biopharmaceutical drug candidate that we believe could become a leader in the market for prevention and treatment of scarring, a market served by specialist physicians – as are all of Shire’s markets.. Shire’s strength in commercialization of specialty products combined with proven experience of building new specialty markets where patient need is high, through the introduction of novel treatments, makes us the ideal partner for Renovo in the development of JUVISTA.”

“We are excited by the potential market opportunity and the profile of this drug candidate, which fits well with our specialty biopharmaceutical focus. Market research shows that surgeons and patients have a high concern for scarring and 90% of surgeons would use a preventative treatment if available. Renovo estimates that the U.S. total market could potentially be worth approximately $4 billion. We look forward to the continued development of JUVISTA.”

Professor Mark W J Ferguson, Renovo’s Chief Executive Officer said:

Registered in England 5492592 Registered Office as above

“We are delighted to have partnered JUVISTA with Shire, which is a leading specialty company with a track record of successfully commercializing specialist pharmaceutical products in new therapeutic areas and an infrastructure which will enable us to maximise JUVISTA’s potential.

“We believe that the two companies will make excellent partners. As the world experts in this field Renovo will continue to be responsible for developing JUVISTA, giving the clinical programme continuity and focus. Shire will provide us with their expert opinion, guidance, and regulatory expertise in successfully getting products to the market.”

Financial terms

The financial terms of the agreement are geared to the success of the development and commercialization of JUVISTA. Following the satisfaction of a Hart Scott-Rodino clearance condition, Shire will pay Renovo US$75 million cash upfront (expensed as R&D for US GAAP purposes) and will make an equity investment in Renovo Group plc of US$50 million (at a subscription price of £2 per share, which at the date of this announcement represents approximately 7% of Renovo’s share capital).

On the FDA’s acceptance of the filing of the biologics license application for JUVISTA, Shire will pay US$25 million and on FDA approval, between US$50 and US$150 million depending on the characteristics of the approved product labelling. In addition, Shire will pay to Renovo royalties on sales of JUVISTA and milestone payments of up to US$ 525 million on the achievement of very significant sales targets.

Shire will bear the cost of clinical trials designed specifically for obtaining US regulatory approval. Renovo will bear the costs of clinical trials designed specifically for obtaining EU regulatory approval. Shire and Renovo will share equally the costs of conducting global clinical trials that are designed for obtaining both US and EU regulatory approvals.

JUVISTA – meeting a high unmet market need

JUVISTA (human TGFβ3) is a novel biopharmaceutical investigational drug and when injected at the time of surgery has been shown in clinical trials to markedly improve subsequent scar appearance in the skin.

JUVISTA has been administered to over 1,500 human subjects and has shown statistical and clinically significant improvements in scarring in four preliminary phase 2 efficacy trials.

Renovo estimates that the U.S. total market could potentially be worth approximately $4 billion with 42 million patients undergoing surgery each year. This includes a large proportion of cash payers. Consumer research shows that 85% of patients would self pay for the reduction or prevention of scarring. Recognizing the changing dynamics of the US health reimbursement and pricing policies, Shire is actively managing the economic risk profile of its overall product portfolio by seeking an entry to the private pay market.

Surgeons have a high concern for scarring in 46% of total patient procedures. 90% of surgeons stated their intention to use a preventative drug (source: Mattson Jack Group).

The majority of patients discuss their concerns regarding scarring with their surgeon prior to surgery and 44% are unhappy with their scar following surgery. 87% of patients wanted their scars to be less noticeable (source: Adelphi International Research consumer study).

Current patient options are limited to treatment of existing formed scars, not the prevention of scarring and comprise OTC (over the counter) products or off-label prescribed steroid injections.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252
Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America)	+1 484 595 8248

Notes to editors

SHIRE PLC

For further information on Shire, please visit the Company’s website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire’s Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of SPD503 (guanfacine extended release) (ADHD); Shire’s ability to secure new products for commercialization and/or development; Shire’s ability to benefit from its acquisition of New River Pharmaceuticals Inc.; the successful development of JUVISTA and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2006.

EX-99.3 5 dp06032e_ex9903.htm Unassociated Document

		EXHIBIT 99.03

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

20 June 2007

Shire plc AGM – 2007

Results of the Annual General Meeting

Shire plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:

		For*	Against	Abstentions
1.	To receive the Companys’ accounts for the year ended 31 December 2006	447,172,037 (99.86%)	618,289 (0.14%)	344,753
2.	To re-elect Dr James Henry Cavanaugh as a director	438,104,602 (97.87%)	9,521,491 (2.13%)	508,986
3.	To re-elect Dr Barry John Price as a director	442,879,006 (98.94%)	4,746,232 (1.06%)	509,841
4.	To elect Ms Kathleen Anne Nealon as a director	445,691,229 (99.59%)	1,829,400 (0.41%)	614,450
5.	To elect Dr Jeffrey Marc Leiden as a director	446,606,331 (99.84%)	722,660 (0.16%)	806,088
6.	To re-elect Mr Matthew William Emmens as a director	443,368,069 (99.27%)	3,263,625 (0.73%)	1,503,385
7.	To re-elect Mr David John Kappler as a director	445,342,529 (99.58%)	1,866,620 (0.42%)	925,930
8.	To re-elect Mr Patrick Jean Marc Langlois as a director	445,769,759 (99.62%)	1,689,983 (0.38%)	675,337
9.	To re-appoint Deloitte & Touche LLP as Auditors	443,403,135 (99.19%)	3,642,175 (0.81%)	1,089,769
10.	To authorise the Audit Committee to determine the remuneration of the Auditors	445,398,735 (99.41%)	2,649,952 (0.59%)	86,392
11.	To approve the Directors’ Remuneration Report	409,534,456 (92.16%)	34,837,916 (7.84%)	3,762,707
12.	To authorise the allotment of shares	438,600,896 (98.07%)	8,651,326 (1.93%)	882,857
13.	To authorise the disapplication of pre-emption rights	445,430,893 (99.55%)	2,019,318 (0.45%)	684,868

Registered in England 5492592 Registered Office as above

14.	To authorise market purchases	447,306,882 (99.99%)	60,523 (0.01%)	767,674
15.	To authorise donations to EU political organisations and EU political expenditure	442,515,165 (99.31%)	3,095,982 (0.69%)	2,523,932
16.	To approve the rules of the 2007 Shire plc Employee Stock Purchase Plan	443,650,279 (99.29%)	3,168,294 (0.71%)	1,316,506

* These figures include discretionary votes

** Abstentions are not counted in the proportion of votes “for” or “against”

T May

Company Secretary

For further information please contact:

Investor Relations		Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
		Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.4 6 dp06032e_ex9904.htm Unassociated Document

		EXHIBIT 99.04

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

Notification of major interests in shares

20 June 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ)

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):

3. Full name of person(s) subject to the notification obligation:	Dr. James Cavanaugh (proxy holder)
4. Full name of shareholder(s) (if different from 3.):	Shareholders appointing Dr. James Cavanaugh as discretionary proxy holder
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	18 June 2007
6. Date on which issuer notified:	20 June 2007
7. Threshold(s) that is/are crossed or reached:	10%
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
	412,849	412,849	412,849	412,849	59,269,521	0.07	10.72

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date	Exercise/Conversion Period/ Date	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Total (A+B)
Number of voting rights	% of voting rights
59,682,370	10.79

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Proxy Voting:

10. Name of the proxy holder:	Dr James Cavanaugh
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:	21 June 2007

13. Additional information:	When proxy expires, 10.72% of voting rights will return to the shareholders that appointed Dr James Cavanaugh as discretionary proxy
14. Contact name:	Vivienne Hemming, Deputy Company Secretary Shire plc
15. Contact telephone number:	+ 44 1256 894276

Annex Notification Of Major Interests In Shares

A: Identity of the person or legal entity subject to the notification obligation
Full name (including legal form for legal entities)
Contact address (registered office for legal entities)
Phone number

Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable
Full name	Dr James Cavanaugh
Contact address	Shire plc Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP
Phone number	+44 1256 894 276
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)	Dr. James Cavanaugh is the Non-Executive Chairman of Shire plc

C: Additional information

This notification is being made because Dr. James Cavanaugh, as Chairman of the meeting has been granted discretionary proxies for the AGM held on 20 June 2007.

T May

Company Secretary

For further information please contact:

Investor Relations		Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
		Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on

attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.5 7 dp06032e_ex9905.htm Unassociated Document

		EXHIBIT 99.05

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

Annual Information Update

20 June 2007

In accordance with the requirements of Prospectus Rule 5.2.1R please find below the Annual Information Update for Shire plc (the "Company"). This is in relation to information that has been published or made available to the public between 21 June 2006 and 19 June 2007.

This Annual Information Update is also being made available on the Investors section of the Company’s website, www.shire.com.

The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.

1. Announcements made via a RIS

The documents listed below were published via a Regulatory Information Service on or around the dates indicated.

21/06/2006		Results of the Annual General Meeting
26/06/2006		Barclays PLC and their holding in Shire
		Goldman Sachs and their holding in Shire
04/07/2006		Holding(s) in Company
07/07/2006		Second Quarter 2006 Results Date Notification
		Correction : Second Quarter 2006 Results 28 July 2006
21/07/2006		SHIRE ANNOUNCES FILING OF SPD465
24/07/2006		Barclays PLC and their holding in Shire
		Shire’s ELAPRASE (TM) Approved by the FDA
27/07/2006		Kate Nealon appointed Non Executive Director at Shire
28/07/2006		Goldman Sachs and their holding in Shire
		Second quarter 2006 results
15/08/2006		Shire and Barr Settle All Pending Litigation
16/08/2006		Purchase of Shares by Employee Benefit Trust
17/08/2006		Purchase of Shares by Employee Benefit Trust
		Fidelity and their holding in Shire
		Goldman Sachs and their holding in Shire

		Barclays PLC and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
18/08/2006		Goldman Sachs and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
		Director/PDMR Shareholding
21/08/2006		Director/PDMR Shareholding
22/08/2006		Purchase of Shares by Employee Benefit Trust
		Barclays PLC and their holding in Shire
		Director/PDMR Shareholding
		Purchase of Shares by Employee Benefit Trust
23/08/2006		Franklin Resources and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
24/08/2006		Jefferies International and their holding in Shire
		Shire Announces NDA Submission Guanfacine for ADHD
		Purchase of Shares by Employee Benefit Trust
25/08/2006		Director/PDMR Shareholding
29/08/2006		Purchase of Shares by Employee Benefit Trust
		Fidelity and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
30/08/2006		Purchase of Shares by Employee Benefit Trust
31/08/2006		Barclays PLC and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
01/09/2006		Purchase of Shares by Employee Benefit Trust
04/09/2006		Purchase of Shares by Employee Benefit Trust
05/09/2006		Purchase of Shares by Employee Benefit Trust
06/09/2006		Purchase of Shares by Employee Benefit Trust
07/09/2006		Purchase of Shares by Employee Benefit Trust
08/09/2006		Shire Provides Update on MESAVANCE (TM)
		Purchase of Shares by Employee Benefit Trust
11/09/2006		Purchase of Shares by Employee Benefit Trust
12/09/2006		Goldman Sachs and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
13/09/2006		Director/PDMR Shareholding
		Purchase of Shares by Employee Benefit Trust
14/09/2006		Holding(s) in Company
15/09/2006		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
18/09/2006		IFRS Information – First half of 2006
		Purchase of Shares by Employee Benefit Trust
19/09/2006		Purchase of Shares by Employee Benefit Trust
20/09/2006		Purchase of Shares by Employee Benefit Trust
21/09/2006		Purchase of Shares by Employee Benefit Trust
22/09/2006		Purchase of Shares by Employee Benefit Trust
25/09/2006		Purchase of Shares by Employee Benefit Trust
27/09/2006		Purchase of Shares by Employee Benefit Trust
		Fidelity and their holding in Shire
		Purchase of Shares by Employee Benefit Trust
28/09/2006		Director/PDMR Shareholding
		Purchase of Shares by Employee Benefit Trust
29/09/2006		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
02/10/2006		Director/PDMR Shareholding
03/10/2006		Director/PDMR Shareholding
		Shire in-licenses development rights
		ADDERALL XR Paragraph IV notice received
		Holding(s) in Company
04/10/2006		Purchase of shares by employee benefit trust
06/10/2006		Purchase of Shares by Employee Benefit Trust

09/10/2006		Regulatory Approval
10/10/2006		Fidelity and their holding in Shire
11/10/2006		Fidelity and their holding in Shire
12/10/2006		Holding(s) in Company
13/10/2006		Q3 2006 RESULTS DATE NOTIFICATION – Oct 27, 2006
		Holding(s) in Company
18/10/2006		Purchase of Shares by Employee Benefit Trust
19/10/2006		ELAPRASE (TM) receives positive opinion in Europe
24/10/2006		Goldman Sachs Group and its holdings in Shire
27/10/2006		Excellent Q3 – upgrading 2006 revenue guidance
30/10/2006		Purchase of Shares by Employee Benefit Trust
07/11/2006		Interim IFRS Report filed with the UK Listing Authority
08/11/2006		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
10/11/2006		Shire sues Andrx Pharmaceuticals, L.L.C.
15/11/2006		Purchase of Shares by Employee Benefit Trust
16/11/2006		Holding(s) in Company
21/11/2006		Director/PDMR Shareholding
		Director/PDMR Shareholding
27/11/2006		Blocklisting - Interim Review
01/12/2006		Director/PDMR Shareholding
12/12/2006		Dr Jeffrey Leiden appointed Non Executive Director
		Director Declaration
14/12/2006		Shire receives label agreement in EU for Mezavant(TM)
15/12/2006		Total Voting Rights
18/12/2006		Holding(s) in Company
19/12/2006		Holding(s) in Company
22/12/2006		New River and Shire Receive Approvable Ltr for VYVANSE
11/01/2007		ELAPRASE approved by the European Commission
12/01/2007		Holding(s) in Company
17/01/2007		FDA Approves LIALDA first once-daily mesalamine for UC
18/01/2007		Total Voting Rights
23/01/2007		Shire licenses the North American rights for SPD754
25/01/2007		Holding(s) in Company
12/02/2007		Director/PDMR Shareholding
14/02/2007		Notice of Results
		Notice of Results
15/02/2007		Total Voting Rights
20/02/2007		Shire Acquires New River
		Equity financing
		Final Results
		RESULT OF EQUITY PLACING
22/02/2007		Director/PDMR Shareholding
23/02/2007		Director/PDMR Shareholding
		Employee Benefit Trust accouncement
26/02/2007		FDA Approval of prodrug VYVANSE for treatment of ADHD
27/02/2007		Director/PDMR Shareholding
28/02/2007		Director/PDMR Shareholding
		Holding(s) in Company
		Holding(s) in Company
		Holding(s) in Company
		Holding(s) in Company
		Holding(s) in Company
01/03/2007		Purchase of Shares by Employee Benefit Trust
02/03/2007		Holding(s) in Company
		Purchase of Shares by Employee Benefit Trust
06/03/2007		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust

08/03/2007		Purchase of Shares by Employee Benefit Trust
09/03/2007		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
13/03/2007		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
14/03/2007		Purchase of Shares by Employee Benefit Trust
16/03/2007		Purchase of Shares by Employee Benefit Trust
		Purchase of Shares by Employee Benefit Trust
19/03/2007		LIALDA with MMX Technology for UC now Available
		Merger Update
		Correction to Purchase of Shares by EBT
20/03/2007		Retirement of David Pendergast at the end of 2007
21/03/2007		Shire files lawsuit
22/03/2007		Holding(s) in Company
		Holding(s) in Company
		Director/PDMR Shareholding
		Purchase of Shares by Employee Benefit Trust
23/03/2007		IFRS results for the year ending December 31, 2006
		Director/PDMR Shareholding
26/03/2007		Purchase of Shares by Employee Benefit Trust
		Notice of EGM
27/03/2007		Purchase of Shares by Employee Benefit Trust
28/03/2007		Purchase of Shares by Employee Benefit Trust
		Holding(s) in Company
29/03/2007		Purchase of Shares by Employee Benefit Trust
30/03/2007		Purchase of Shares by Employee Benefit Trust
02/04/2007		Director/PDMR Shareholding
		Total Voting Rights
		Shire Executive Annual Incentive Plan
03/04/2007		Purchase of Shares by Employee Benefit Trust
		Additional Listing
04/04/2007		Shire Executive Annual Incentive Plan
		Director/PDMR Shareholding
		Director/PDMR Shareholding
05/04/2007		Purchase of Shares by Employee Benefit Trust
		Movement of shares out of the Employee Benefit Trust
10/04/2007		Purchase of Shares by Employee Benefit Trust
16/04/2007		Results of EGM held on 16 April 2007
		Holding(s) in Company
17/04/2007		Notice of Results - First Quarter 2007
		Notice of Results - First Quarter 2007
18/04/2007		Tender Offer for New River Shares Successfully completed
20/04/2007		Shire Completes Acquisition of New River
25/04/2007		1st Quarter Results
01/05/2007		Total Voting Rights
02/05/2007		Shire plc announces refinancing of bank facilities
		Pricing of US$1,000 million Convertible Bonds due 2014
03/05/2007		VYVANSE(TM) Receives Final DEA Schedule Classification
		Publication of Offering Circular
08/05/2007		Shire announces the Exercise of Over-Allotment Option
11/05/2007		Retirement of Non-Executive Director
18/05/2007		Director/PDMR Shareholding
21/05/2007		FDA Issues Approvable Letter for SPD465
22/05/2007		Director/PDMR Shareholding
29/05/2007		Blocklisting - Interim Review
01/06/2007		Total Voting Rights
19/06/2007		Holding(s) in Company

2. Documents filed at Companies House

All documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated, and can be obtained from Companies House via their website www.companieshouse.gov.uk.

Date

Document

30/06/2006		Form 88(2)R - Return of an Allotment of Shares
30/06/2006		Form 88(2)R - Return of an Allotment of Shares
30/06/2006		Form 88(2)R - Return of an Allotment of Shares
30/06/2006		Form 88(2)R - Return of an Allotment of Shares
07/07/2006		Form 88(2)R - Return of an Allotment of Shares
07/07/2006		Form 88(2)R - Return of an Allotment of Shares
11/07/2006		Form 88(2)R - Return of an Allotment of Shares
14/07/2006		Form 88(2)R - Return of an Allotment of Shares
17/07/2006		Form 88(2)R - Return of an Allotment of Shares
18/07/2006		Form 88(2)R - Return of an Allotment of Shares
18/07/2006		Form 88(2)R - Return of an Allotment of Shares
18/07/2006		Form 88(2)R - Return of an Allotment of Shares
18/07/2006		Form 363s - Annual Return
19/07/2006		Form 88(2)R - Return of an Allotment of Shares
20/07/2006		Form 88(2)R - Return of an Allotment of Shares
24/07/2006		Form 88(2)R - Return of an Allotment of Shares
25/07/2006		Form 88(2)R - Return of an Allotment of Shares
27/07/2006		Form 88(2)R - Return of an Allotment of Shares
27/07/2006		Form 88(2)R - Return of an Allotment of Shares
27/07/2006		Form 288a – Appointment of a Director
28/07/2006		Form 88(2)R - Return of an Allotment of Shares
01/08/2006		Form 88(2)R - Return of an Allotment of Shares
02/08/2006		Form 88(2)R - Return of an Allotment of Shares
03/08/2006		Form 88(2)R - Return of an Allotment of Shares
07/08/2006		Form 88(2)R - Return of an Allotment of Shares
07/08/2006		Form 88(2)R - Return of an Allotment of Shares
09/08/2006		Form 88(2)R - Return of an Allotment of Shares
10/08/2006		Form 88(2)R - Return of an Allotment of Shares
11/08/2006		Form 88(2)R - Return of an Allotment of Shares
14/08/2006		Form 88(2)R - Return of an Allotment of Shares
14/08/2006		Form 88(2)R - Return of an Allotment of Shares
15/08/2006		Form 88(2)R - Return of an Allotment of Shares
16/08/2006		Form 88(2)R - Return of an Allotment of Shares
17/08/2006		Form 88(2)R - Return of an Allotment of Shares
18/08/2006		Form 88(2)R - Return of an Allotment of Shares
21/08/2006		Form 88(2)R - Return of an Allotment of Shares
22/08/2006		Form 88(2)R - Return of an Allotment of Shares
24/08/2006		Form 88(2)R - Return of an Allotment of Shares
25/08/2006		Form 88(2)R - Return of an Allotment of Shares
25/08/2006		Form 88(2)R - Return of an Allotment of Shares
29/08/2006		Form 88(2)R - Return of an Allotment of Shares
29/08/2006		Form 88(2)R - Return of an Allotment of Shares
31/08/2006		Form 88(2)R - Return of an Allotment of Shares

01/09/2006		Form 88(2)R - Return of an Allotment of Shares
04/09/2006		Form 88(2)R - Return of an Allotment of Shares
05/09/2006		Form 88(2)R - Return of an Allotment of Shares
05/09/2006		Form 88(2)R - Return of an Allotment of Shares
06/09/2006		Form 88(2)R - Return of an Allotment of Shares
11/09/2006		Form 88(2)R - Return of an Allotment of Shares
11/09/2006		Form 88(2)R - Return of an Allotment of Shares
13/09/2006		Form 88(2)R - Return of an Allotment of Shares
13/09/2006		Form 88(2)R - Return of an Allotment of Shares
04/10/2006		Form 88(2)R - Return of an Allotment of Shares
04/10/2006		Form 88(2)R - Return of an Allotment of Shares
04/10/2006		Form 88(2)R - Return of an Allotment of Shares
04/10/2006		Form 88(2)R - Return of an Allotment of Shares
09/10/2006		Form 88(2)R - Return of an Allotment of Shares
09/10/2006		Form 88(2)R - Return of an Allotment of Shares
09/10/2006		Form 88(2)R - Return of an Allotment of Shares
09/10/2006		Form 88(2)R - Return of an Allotment of Shares
13/10/2006		Form 88(2)R - Return of an Allotment of Shares
13/10/2006		Form 88(2)R - Return of an Allotment of Shares
13/10/2006		Form 88(2)R - Return of an Allotment of Shares
13/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
16/10/2006		Form 88(2)R - Return of an Allotment of Shares
18/10/2006		Form 88(2)R - Return of an Allotment of Shares
19/10/2006		Form 88(2)R - Return of an Allotment of Shares
20/10/2006		Form 88(2)R - Return of an Allotment of Shares
23/10/2006		Form 88(2)R - Return of an Allotment of Shares
23/10/2006		Form 88(2)R - Return of an Allotment of Shares
24/10/2006		Form 88(2)R - Return of an Allotment of Shares
25/10/2006		Form 88(2)R - Return of an Allotment of Shares
26/10/2006		Form 88(2)R - Return of an Allotment of Shares
30/10/2006		Form 88(2)R - Return of an Allotment of Shares
31/10/2006		Form 88(2)R - Return of an Allotment of Shares
02/11/2006		Form 88(2)R - Return of an Allotment of Shares
06/11/2006		Form 88(2)R - Return of an Allotment of Shares
06/11/2006		Form 88(2)R - Return of an Allotment of Shares
08/11/2006		Form 88(2)R - Return of an Allotment of Shares
09/11/2006		Form 88(2)R - Return of an Allotment of Shares
10/11/2006		Form 88(2)R - Return of an Allotment of Shares
13/11/2006		Form 88(2)R - Return of an Allotment of Shares
14/11/2006		Form 88(2)R - Return of an Allotment of Shares
15/11/2006		Form 88(2)R - Return of an Allotment of Shares
17/11/2006		Form 88(2)R - Return of an Allotment of Shares
17/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares

24/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares
24/11/2006		Form 88(2)R - Return of an Allotment of Shares
27/11/2006		Form 88(2)R - Return of an Allotment of Shares
27/11/2006		Form 122
28/11/2006		Form 88(2)R - Return of an Allotment of Shares
28/11/2006		Form 88(2)R - Return of an Allotment of Shares
29/11/2006		Form 88(2)R - Return of an Allotment of Shares
29/11/2006		Form 88(2)R - Return of an Allotment of Shares
30/11/2006		Form 88(2)R - Return of an Allotment of Shares
30/11/2006		Form 88(2)R - Return of an Allotment of Shares
04/12/2006		Form 88(2)R - Return of an Allotment of Shares
04/12/2006		Form 88(2)R - Return of an Allotment of Shares
04/12/2006		Form 88(2)R - Return of an Allotment of Shares
04/12/2006		Form 88(2)R - Return of an Allotment of Shares
04/12/2006		Form 88(2)R - Return of an Allotment of Shares
05/12/2006		Form 88(2)R - Return of an Allotment of Shares
06/12/2006		Form 88(2)R - Return of an Allotment of Shares
06/12/2006		Form 88(2)R - Return of an Allotment of Shares
07/12/2006		Form 88(2)R - Return of an Allotment of Shares
07/12/2006		Form 88(2)R - Return of an Allotment of Shares
07/12/2006		Form 88(2)R - Return of an Allotment of Shares
08/12/2006		Form 88(2)R - Return of an Allotment of Shares
08/12/2006		Form 88(2)R - Return of an Allotment of Shares
08/12/2006		Form 88(2)R - Return of an Allotment of Shares
11/12/2006		Form 88(2)R - Return of an Allotment of Shares
11/12/2006		Form 88(2)R - Return of an Allotment of Shares
12/12/2006		Form 88(2)R - Return of an Allotment of Shares
13/12/2006		Form 88(2)R - Return of an Allotment of Shares
14/12/2006		Form 88(2)R - Return of an Allotment of Shares
15/12/2006		Form 88(2)R - Return of an Allotment of Shares
15/12/2006		Form 88(2)R - Return of an Allotment of Shares
15/12/2006		Form 88(2)R - Return of an Allotment of Shares
19/12/2006		Form 88(2)R - Return of an Allotment of Shares
19/12/2006		Form 88(2)R - Return of an Allotment of Shares
20/12/2006		Form 88(2)R - Return of an Allotment of Shares
20/12/2006		Form 88(2)R - Return of an Allotment of Shares
21/12/2006		Form 88(2)R - Return of an Allotment of Shares
21/12/2006		Form 88(2)R - Return of an Allotment of Shares
02/01/2007		Form 88(2)R - Return of an Allotment of Shares
02/01/2007		Form 88(2)R - Return of an Allotment of Shares
02/01/2007		Form 88(2)R - Return of an Allotment of Shares
02/01/2007		Form 88(2)R - Return of an Allotment of Shares
02/01/2007		Form 288a – Appointment of a Director
03/01/2007		Form 88(2)R - Return of an Allotment of Shares
03/01/2007		Form 88(2)R - Return of an Allotment of Shares
03/01/2007		Form 88(2)R - Return of an Allotment of Shares
10/01/2007		Form 88(2)R - Return of an Allotment of Shares
10/01/2007		Form 88(2)R - Return of an Allotment of Shares
10/01/2007		Form 88(2)R - Return of an Allotment of Shares

11/01/2007		Form 88(2)R - Return of an Allotment of Shares
12/01/2007		Form 88(2)R - Return of an Allotment of Shares
15/01/2007		Form 88(2)R - Return of an Allotment of Shares
16/01/2007		Form 88(2)R - Return of an Allotment of Shares
16/01/2007		Form 88(2)R - Return of an Allotment of Shares
17/01/2007		Form 88(2)R - Return of an Allotment of Shares
17/01/2007		Form 88(2)R - Return of an Allotment of Shares
17/01/2007		Form 88(2)R - Return of an Allotment of Shares
19/01/2007		Form 88(2)R - Return of an Allotment of Shares
19/01/2007		Form 88(2)R - Return of an Allotment of Shares
19/01/2007		Form 88(2)R - Return of an Allotment of Shares
19/01/2007		Form 288b - Resignation of a Director
23/01/2007		Form 88(2)R - Return of an Allotment of Shares
23/01/2007		Form 88(2)R - Return of an Allotment of Shares
24/01/2007		Form 88(2)R - Return of an Allotment of Shares
24/01/2007		Form 88(2)R - Return of an Allotment of Shares
26/01/2007		Form 88(2)R - Return of an Allotment of Shares
26/01/2007		Form 88(2)R - Return of an Allotment of Shares
26/01/2007		Form 88(2)R - Return of an Allotment of Shares
29/01/2007		Form 88(2)R - Return of an Allotment of Shares
29/01/2007		Form 88(2)R - Return of an Allotment of Shares
30/01/2007		Form 88(2)R - Return of an Allotment of Shares
01/02/2007		Form 88(2)R - Return of an Allotment of Shares
01/02/2007		Form 88(2)R - Return of an Allotment of Shares
01/02/2007		Form 88(2)R - Return of an Allotment of Shares
06/02/2007		Form 88(2)R - Return of an Allotment of Shares
06/02/2007		Form 88(2)R - Return of an Allotment of Shares
06/02/2007		Form 88(2)R - Return of an Allotment of Shares
09/02/2007		Form 88(2)R - Return of an Allotment of Shares
09/02/2007		Form 88(2)R - Return of an Allotment of Shares
14/02/2007		Form 88(2)R - Return of an Allotment of Shares
14/02/2007		Form 88(2)R - Return of an Allotment of Shares
14/02/2007		Form 88(2)R - Return of an Allotment of Shares
16/02/2007		Form 88(2)R - Return of an Allotment of Shares
16/02/2007		Form 88(2)R - Return of an Allotment of Shares
16/02/2007		Form 88(2)R - Return of an Allotment of Shares
21/02/2007		Form 88(2)R - Return of an Allotment of Shares
21/02/2007		Form 88(2)R - Return of an Allotment of Shares
21/02/2007		Form 88(2)R - Return of an Allotment of Shares
26/02/2007		Form 88(2)R - Return of an Allotment of Shares
27/02/2007		Form 88(2)R - Return of an Allotment of Shares
28/02/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
14/03/2007		Form 88(2)R - Return of an Allotment of Shares
23/03/2007		Form 88(2)R - Return of an Allotment of Shares

23/03/2007		Form 88(2)R - Return of an Allotment of Shares
23/03/2007		Form 88(2)R - Return of an Allotment of Shares
23/03/2007		Form 88(2)R - Return of an Allotment of Shares
27/03/2007		Form 88(2)R - Return of an Allotment of Shares
27/03/2007		Form 88(2)R - Return of an Allotment of Shares
27/03/2007		Form 88(2)R - Return of an Allotment of Shares
04/04/2007		Form 88(2)R - Return of an Allotment of Shares
04/04/2007		Form 88(2)R - Return of an Allotment of Shares
04/04/2007		Form 88(2)R - Return of an Allotment of Shares
04/04/2007		Form 88(2)R - Return of an Allotment of Shares
04/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
16/04/2007		Form 88(2)R - Return of an Allotment of Shares
18/04/2007		Form 88(2)R - Return of an Allotment of Shares
18/04/2007		Form 88(2)R - Return of an Allotment of Shares
18/04/2007		Form 88(2)R - Return of an Allotment of Shares
23/04/2007		Form 88(2)R - Return of an Allotment of Shares
23/04/2007		Form 88(2)R - Return of an Allotment of Shares
23/04/2007		Form 88(2)R - Return of an Allotment of Shares
23/04/2007		Form 88(2)R - Return of an Allotment of Shares
27/04/2007		Form 88(2)R - Return of an Allotment of Shares
27/04/2007		Form 88(2)R - Return of an Allotment of Shares
27/04/2007		Form 88(2)R - Return of an Allotment of Shares
02/05/2007		Form 88(2)R - Return of an Allotment of Shares
02/05/2007		Form 88(2)R - Return of an Allotment of Shares
02/05/2007		Form 88(2)R - Return of an Allotment of Shares
02/05/2007		Form 88(2)R - Return of an Allotment of Shares
02/05/2007		Form 88(2)R - Return of an Allotment of Shares
04/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 88(2)R - Return of an Allotment of Shares
10/05/2007		Form 288b – Resignation of a Director
16/05/2007		Form 88(2)R - Return of an Allotment of Shares
16/05/2007		Form 88(2)R - Return of an Allotment of Shares
16/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
24/05/2007		Form 88(2)R - Return of an Allotment of Shares
30/05/2007		Form 88(2)R - Return of an Allotment of Shares
30/05/2007		Form 88(2)R - Return of an Allotment of Shares
30/05/2007		Form 88(2)R - Return of an Allotment of Shares

30/05/2007		Form 88(2)R - Return of an Allotment of Shares
06/06/2007		Form 88(2)R - Return of an Allotment of Shares
06/06/2007		Form 88(2)R - Return of an Allotment of Shares
06/06/2007		Form 88(2)R - Return of an Allotment of Shares
06/06/2007		Form 88(2)R - Return of an Allotment of Shares
12/06/2007		Form 88(2)R - Return of an Allotment of Shares
12/06/2007		Form 88(2)R - Return of an Allotment of Shares
12/06/2007		Form 88(2)R - Return of an Allotment of Shares
12/06/2007		Form 88(2)R - Return of an Allotment of Shares
12/06/2007		Form 88(2)R - Return of an Allotment of Shares

3. Documents filed with the Securities and Exchange Commission (“SEC”)

The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC’s website at www.sec.gov.

4. Documents sent to Shareholders

The following documents were published and sent to shareholders. They are available on the Company’s website.

Date		Document

26/03/2007		Notice of Extraordinary General Meeting
21/05/2007		Annual Report and Accounts
21/05/2007		Notice of Annual General Meeting

A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.

T May

Company Secretary

For further information please contact:

Investor Relations		Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
		Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.6 8 dp06032e_ex9906.htm Unassociated Document

		EXHIBIT 99.06

	Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

	Press Release

Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD

Basingstoke, U.K., and Philadelphia, U.S. – June 21, 2007– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Unlike some other ADHD treatments, INTUNIV, a nonstimulant, is not a controlled substance and does not have a known mechanism for potential abuse or dependence. The information requested by the FDA was not unexpected, and Shire is working with the FDA to provide a full and timely response to the agency’s request.

“The FDA’s approvable letter for INTUNIV is positive news, and Shire will be working closely with the agency to address its questions,” said Matthew Emmens, CEO of Shire. “When approved, INTUNIV will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks. Shire is looking forward to further strengthening our broad portfolio of ADHD medications by adding a nonstimulant treatment option with a novel mechanism of action and demonstrated clinical efficacy, which may be ideal for those patients who have not benefited from currently available ADHD medications.”

About INTUNIV (guanfacine) Extended Release Tablets

Shire is seeking approval of INTUNIV as monotherapy for the treatment of ADHD symptoms throughout the day in children aged 6 to 17 years, with dosage strengths of 1 mg to 4 mg daily. The INTUNIV New Drug Application (NDA) includes data from two placebo-controlled trials in children and adolescents ages 6 to 17 evaluating the compound’s safety and efficacy in controlling ADHD symptoms evaluated on a once-weekly basis using the ADHD Rating Scale (ADHD-RS-IV), which included both hyperactive/impulsive and inattentive subscales. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD in children and for assessing their response to treatment. This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision®. In these two clinical trials, treatment related adverse events greater than 10 percent included somnolence, fatigue, upper abdominal pain, sedation and headache.

INTUNIV, a once-daily formulation of guanfacine, provides a controlled, steady delivery of drug throughout the day and evening with a delivery system that minimizes the fluctuations between peak and trough concentrations as seen with immediate-release guanfacine. It has been shown that guanfacine, the active ingredient in INTUNIV, binds selectively to alpha 2A adrenergic cell receptors located in the part of the brain called the prefrontal cortex. The prefrontal cortex is an area of the brain associated with executive functioning, i.e., working memory, behavioral inhibition, regulation of attention, distractibility, impulsivity, and frustration tolerance. The selective alpha-2A agonist strengthens working memory and prefrontal cortex neuronal firing. This research supports the use of guanfacine for the treatment of ADHD.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the CDC. ADHD is one of the most common psychiatric disorders in children and adolescents. The disorder is also estimated to affect approximately 9.8 million adults across the U.S. based on a retrospective survey of adults aged 18 to 44, projected to the full U.S. adult population. ADHD is a neurological brain disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no “cure” for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America)	+1 484 595 8248

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire’s Attention Deficit and Hyperactivity Disorder (“ADHD”) franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV^™ (guanfacine) extended release (ADHD); Shire’s ability to secure new products for commercialization and/or development; Shire’s ability to benefit from its acquisition of New River Pharmaceuticals Inc.; the successful development of JUVISTA^®, and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2006.